Usa hospital covid-19 death patient Usa

Study: Remdesivir benefits some COVID-19 patients

Reading now: 258
www.cidrap.umn.edu

A study published late last week in the New England Journal of Medicine found that hospitalized COVID-19 patients who received Gilead Sciences' antiviral drug remdesivir recovered a median of 4 days earlier than those who received a placebo.Preliminary findings from the double-blind Adaptive COVID-19 Treatment Trial (ACTT-1), sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), showed that the 538 patients randomly assigned to receive remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), compared with 15 days (95% CI, 13 to 19) in the 521 patients who received a placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P < 0.001).The patients were enrolled from Feb 21 to

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA